We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NTD Drug Development Outlined in US FDA Draft Guidance
NTD Drug Development Outlined in US FDA Draft Guidance
September 8, 2011
Clarification of regulatory requirements and internal review standards for neglected tropical disease (NTD) drug approvals in the U.S. appears in a U.S. Food and Drug Administration (FDA) draft guidance.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor